Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jesus San Miguel

Showing results (1-10 of 145) with videos related to

Pageof 15
Sort By:
Hematology. American Society of Hematology. Education Program|February 20, 2015
Multiple myeloma: a model for scientific and clinical progressJesus San Miguel
Blood|November 2, 2013
Can CRd be a standard for refractory myeloma?Jesus San-Miguel
Hematology/Oncology Clinics of North America|November 13, 2007
Prognostic factors and staging in multiple myelomaRafael Fonseca, Jesus San Miguel
Blood|May 13, 2022
MRD in multiple myeloma: does CR really matter?Bruno Paiva, Jesus San-Miguel, Hervé Avet-Loiseau
The Lancet. Oncology|July 31, 2025
Unpublished overall survival confounders in immunomodulatory agent registrational trials - Authors' replyJesus San-Miguel, Paul Richardson, Meletios A Dimopoulos
Cancer Treatment Reviews|November 22, 2005
Bortezomib, a novel proteasome inhibitor, in the treatment of hematologic malignanciesGraham Jackson, Hermann Einsele, Phillippe Moreau, et al.
Cancer Journal (Sudbury, Mass.)|December 17, 2009
Risk stratification in the era of novel therapiesJesus San-Miguel, M Victoria Mateos, Norma C Gutierrez
Seminars in Hematology|April 25, 2009
Frontline treatment in elderly patients with multiple myelomaThierry Facon, Jesus San Miguel, Maria Victoria Mateos, et al.
British Journal of Haematology|June 11, 2021
Pembrolizumab combined with carfilzomib and low-dose dexamethasone for relapsed or refractory multiple myeloma: Cohort 2 of the phase I KEYNOTE-023 studyPhilippe Moreau, Razi Ghori, Mohammed Farooqui, et al.
Scientific Data|February 27, 2019
A 1980-2018 global fire danger re-analysis dataset for the Canadian Fire Weather IndicesClaudia Vitolo, Francesca Di Giuseppe, Blazej Krzeminski, et al.
Pageof 15

Showing results (1-10 of 145) with videos related to

Sort By:
Pageof 15
Hematology. American Society of Hematology. Education Program|February 20, 2015
Multiple myeloma: a model for scientific and clinical progressJesus San Miguel
Blood|November 2, 2013
Can CRd be a standard for refractory myeloma?Jesus San-Miguel
Hematology/Oncology Clinics of North America|November 13, 2007
Prognostic factors and staging in multiple myelomaRafael Fonseca, Jesus San Miguel
Blood|May 13, 2022
MRD in multiple myeloma: does CR really matter?Bruno Paiva, Jesus San-Miguel, Hervé Avet-Loiseau
The Lancet. Oncology|July 31, 2025
Unpublished overall survival confounders in immunomodulatory agent registrational trials - Authors' replyJesus San-Miguel, Paul Richardson, Meletios A Dimopoulos
Cancer Treatment Reviews|November 22, 2005
Bortezomib, a novel proteasome inhibitor, in the treatment of hematologic malignanciesGraham Jackson, Hermann Einsele, Phillippe Moreau, et al.
Cancer Journal (Sudbury, Mass.)|December 17, 2009
Risk stratification in the era of novel therapiesJesus San-Miguel, M Victoria Mateos, Norma C Gutierrez
Seminars in Hematology|April 25, 2009
Frontline treatment in elderly patients with multiple myelomaThierry Facon, Jesus San Miguel, Maria Victoria Mateos, et al.
British Journal of Haematology|June 11, 2021
Pembrolizumab combined with carfilzomib and low-dose dexamethasone for relapsed or refractory multiple myeloma: Cohort 2 of the phase I KEYNOTE-023 studyPhilippe Moreau, Razi Ghori, Mohammed Farooqui, et al.
Scientific Data|February 27, 2019
A 1980-2018 global fire danger re-analysis dataset for the Canadian Fire Weather IndicesClaudia Vitolo, Francesca Di Giuseppe, Blazej Krzeminski, et al.
Pageof 15